SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

Ersodetug

LGND·LIGAND PHARMACEUTICALS INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
If the full upLIFT results (expected mid-December 2026) remain positive, Rezolute could file a Biologics License Application (BLA) for tumor hyperinsulinism in 2027. The congenital HI path is less clear after the sunRIZE miss, though the FDA has recommended a pre-BLA meeting. Analyst projections from 2025 suggested a potential market launch in 2027 for at least one indication.
Why 4/10
The next hard catalyst is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. For LGND, ersodetug is a minor royalty asset among 200+, so this catalyst has limited impact on LGND's share price. ImpactScore is 4 because there is a dated binary readout within ~1 month, but it drives only a small fraction of LGND's diversified royalty portfolio value.
Actionable Insight NEUTRAL

The next hard catalyst for ersodetug is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. Positive results would support a BLA filing for tumor HI, while the congenital HI path remains uncertain after the sunRIZE miss. For LGND holders, this is a minor portfolio contributor; for RZLT holders, it is the primary value driver.

Price Chart

Loading chart...

Executive Summary

Ersodetug (RZ358) is a monoclonal antibody insulin-receptor antagonist being developed by Rezolute (RZLT) for hypoglycemia caused by hyperinsulinism. The drug had a mixed clinical record: the Phase 3 sunRIZE study in congenital hyperinsulinism failed its primary endpoint in December 2025, but the Phase 3 upLIFT study in tumor hyperinsulinism met its primary endpoint with 13 of 16 responders, announced today (November 13, 2026). Through Ligand's $739M acquisition of XOMA Royalty (closed July 2026), Ligand (LGND) holds high-single to mid-teen percentage royalty rights on any future ersodetug sales. However, ersodetug is one of 200+ royalty assets in Ligand's portfolio and represents a very small fraction of its diversified revenue stream, making it a minor factor for LGND shareholders.

How It Works

Ersodetug is a lab-made antibody (a fully human monoclonal antibody) that blocks the insulin receptor. In patients with hyperinsulinism, the body produces too much insulin, causing dangerously low blood sugar. Ersodetug acts as an insulin antagonist, preventing excess insulin from signaling cells to absorb too much glucose, thereby raising and stabilizing blood sugar levels.

Trial Status

Two Phase 3 trials have been completed: sunRIZE (congenital HI) failed its primary endpoint in December 2025; upLIFT (tumor HI) met its primary endpoint with positive preliminary results announced November 13, 2026. Full topline results for upLIFT are expected by mid-December 2026. The FDA has recommended a pre-BLA meeting for the congenital HI program despite the sunRIZE miss.

The Two-Sided Case

▲ Bull Case5
The Phase 3 upLIFT study in tumor hyperinsulinism met its primary efficacy endpoint, with 13 of 16 participants achieving the response criterion.
Ersodetug has both FDA Breakthrough Therapy Designation and Orphan Drug Designation for tumor HI, which could accelerate development and review.
Through the XOMA acquisition (closed July 2026), Ligand holds high-single to mid-teen percentage royalty rights on any future ersodetug sales.
Analyst consensus on RZLT is Strong Buy with a mean price target of $10.10, implying 161% upside from the $3.87 close.
LGND has strong analyst support (16 Buy/Strong Buy ratings, mean target $361, 14% upside) and Q3 2026 royalty revenue grew 51% YoY to $70.3M.
▼ Bear Case5
The Phase 3 sunRIZE study in congenital hyperinsulinism failed its primary endpoint in December 2025, leaving the regulatory path for that larger indication unresolved.
Rezolute priced a $100M stock offering concurrently with the positive upLIFT news, diluting existing shareholders.
Tumor hyperinsulinism is an ultra-rare condition with limited commercial upside; peak sales estimates for ersodetug are only around $300M.
For LGND, the ersodetug royalty is one of 200+ assets in the portfolio and represents a very small fraction of total royalty revenue.
The upLIFT results are preliminary (13 of 16 responders) and full statistical analysis is still pending.

Upcoming Catalysts

  • Full topline results from Phase 3 upLIFT study in tumor HI (expected by mid-December 2026)
  • Pre-BLA meeting with FDA for congenital HI program (timing TBD)
  • Potential BLA submission for tumor HI if full upLIFT results remain positive

Source Filing

The SecBot filing or press-release report that triggered this drug report:

LIGAND PHARMACEUTICALS INC 8-K LGND ·Originating report

Sources · 12

Hover a chip for the title
1 rttnews.com2 markets.businessinsider.com3 investing.com4 fiercepharma.com5 markets.financialcontent.com6 healio.com7 msn.com8 markets.businessinsider.com9 nasdaq.com10 empr.com11 grafa.com12 markets.financialcontent.com